Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01622556 · ClinicalTrials.gov registry record · Phase 2
Conditioning Treatment With Umbilical Cord Blood Transplant for Hematologic Malignancies
A Phase 2 study, sponsored by University of Virginia.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT01622556 is a Phase 2 study that was terminated before completion, run by University of Virginia. The registered enrollment target is 6 participants.
The verdict
NCT01622556, a Phase 2 study, was terminated before completion, sponsored by University of Virginia.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
This is a phase II study to assess the day 180 event free and overall survival after administration of a specified combination of fludarabine, busulfan, Total Body Irradiation (TBI), and thymoglobulin reduced intensity conditioning and 2 unit UCB stem cell transplant in a single institution setting in patients with hematologic malignancies for whom allogeneic transplantation is indicated.
Interventions
- DRUG Fludarabine
- DRUG Busulfan
- DRUG Thymoglobulin
- RADIATION Total Body Irradiation
- BIOLOGICAL Umbilical Cord Blood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2012-01 |
| Est. Completion | 2017-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01622556
The ClinicalTrials.gov registry entry for NCT01622556 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Virginia, which has 449 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Fludarabine is the first listed.
NCT01622556 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01622556 about?
NCT01622556 is a clinical study titled "Conditioning Treatment With Umbilical Cord Blood Transplant for Hematologic Malignancies". This is a phase II study to assess the day 180 event free and overall survival after administration of a specified combination of fludarabine, busulfan, Total Body Irradiation (TBI), and thymoglobulin reduced intensity conditioning and 2 unit UCB stem cell transplant in a single institution setting ...
What is the current status of trial NCT01622556?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2012-01. Estimated completion is 2017-01.
What interventions are being tested in trial NCT01622556?
The interventions under investigation include: Fludarabine (DRUG), Busulfan (DRUG), Thymoglobulin (DRUG), Total Body Irradiation (RADIATION), Umbilical Cord Blood (BIOLOGICAL).
Who is sponsoring clinical trial NCT01622556?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.